Abstract 443P
Background
The low survival rate of cancer patients, especially patients who got metastases, necessitates an approach in providing additional therapy that is safe, capable of delaying disease progression, and prolonging patient survival. Vitamin D is an adjunctive therapy that is easy to obtain and shows anti-neoplastic activity against cancer so that it can reduce mortality. This study aimed to conduct a systematic review and meta-analysis regarding the efficacy of vitamin D supplementation in overall survival (OS) of cancer patients.
Methods
A systematic search of various databases up to end of 2022 was conducted to identify Randomized Controlled Trials (RCTs) involving the efficacy of vitamin D supplementation in OS of cancer patients. By using a random effect model, pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated to determine the values of OS. In formulating the study problem, we determine the study questions based on the study background, which consists of the populations (P), interventions (I), comparisons (C), and outcomes (O). The populations were cancer patients. The intervention was administration of vitamin D supplementation. The comparison was no administration of vitamin D supplementation. The outcome was OS. The RCTs having cancer patients over 18 years of age with available and sufficient information about OS were the inclusion criteria of this study. Study that has participants taking vitamin D supplementation regularly, and ongoing study with results not presented or published at the time of the literature search were the exclusion criteria of this study.
Results
Of the six RCTs, analysis was performed on 1,916 cancer patients in this study. In terms of survival, statistically, there was no difference in OS [HR 0.97, 95% CI 0.74 – 1.28, p = 0.85] between vitamin D supplementation and no supplementation in cancer patients.
Conclusions
Although vitamin D supplementation does not improve OS in cancer patients, is could be considered because it still shows benefits for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract